Cytosorbents 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third quarter 2026 revenue was $9.7 million, up 3% year over year and 1% sequentially, with distributor and strategic partner sales up 18% year over year.
- Product gross margin was 75%, compared with 73% in the second quarter and 70% a year ago; gross profit rose 10% to $7.3 million and cost of goods sold declined 15% to $2.4 million.
- Operating expenses were $8.5 million, down 11% year over year; SG&A fell 18% to $7.1 million, while R&D was $1.1 million.
- Operating loss improved 59% to $1.2 million, and adjusted EBITDA loss narrowed 86% to approximately $284,000 from $2 million a year ago.
- Net loss was $1.8 million, or $0.58 per share, compared with $3.2 million, or $1.01 per share; adjusted net loss was $1.5 million, or $0.48 per share.
- The company generated approximately $43,000 of positive operating cash flow in the third quarter, excluding $251,000 of restructuring payments; including restructuring, total cash burn was $200,000.
- Cash, cash equivalents, and restricted cash totaled $5.7 million at quarter-end, inventory fell to $3.2 million from $5.3 million at year-end, and year-to-date cash used in operations was $2 million versus $7.6 million last year.
- For the 9 months ended September, revenue was $28.2 million, up 1%; gross margin improved to 73% from 71%, operating expenses fell 9% to $27.4 million, and adjusted EBITDA loss improved 45% to $4 million.
- Germany represented 24% of third-quarter sales and declined approximately 20% to 21% year over year; distributor and strategic partner sales and direct international sales outside Germany accounted for 76% of sales.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, ladies and gentlemen, and welcome to CytoSorbents' third quarter earnings conference call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded on Thursday, November 12, 2026. I would now like to turn the conference over to Pete Mariani, Chief Financial Officer.
Please go ahead. Thank you, John, and good afternoon, everyone.
Joining me on today's call is Dr. Phillip Chan, our Chief Executive Officer. As we get started this evening, I want to remind everyone that our press release has been filed and is available with the SEC, but in the several delays that many of us have experienced today, apparently there's a delay with the wire service, so hopefully we'll see that cross the wire here very soon. On today's call, we will review our third quarter 2026 operating and financial results, including the key milestone highlighted in today's earnings release, the achievement of our first value driver, operating cash flow breakeven. We will then provide an update on our remaining value drivers, including our regulatory progress with DrugSorb-ATR, followed by a question-and-answer session.
Before we begin, I'd like to remind everyone that statements made during this call that are not historical facts are forward-looking statements, and the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements about our plans, objectives, future targets and outlook, our ability to sustain operating cash flow breakeven, the outcome of our regulatory submissions, our ability to maintain compliance with NASDAQ continued listing requirements, and our ability to finance the company, including the extension, refinancing, or repayment of our existing debt. Actual results may differ materially from those expressed or implied in these statements.
For the discussion of risks and uncertainties that could cause such differences, please refer to the risk factors in our annual report on Form 10-K filed with the SEC on March 30, 2026, as updated by our quarterly reports on Form 10-Q, including the 10-Q we expect to file by Monday, November 16. We undertake no obligation to update any forward-looking statements, except as required by law. During this call, we will also refer to certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net loss, and adjusted net loss per share. Reconciliations of these measures to the most directly comparable GAAP measures are included in our earnings press release, which is available on the investor relations section of our website. Also note that our share and per-share amounts reflect the 1-for-20 reverse stock split affected on September 8, 2026. With that, I'll turn the call over to Phil.
Phil? Great. Thank you very much, Pete.
Just a moment, please. Well, thanks, Pete, and good afternoon, everyone. I appreciate you joining us. This was an important quarter for CytoSorbents, not just because of the financial results, but because of what they tell us about the business that we're building. We set a clear objective to reach operating cash flow breakeven in the second half of 2026. I'm pleased to report that we achieved that objective in the third quarter, excluding restructuring-related payments. We generated approximately $43,000 of positive operating cash flow on that basis. Revenue was $9.7 million. Product gross margins reached 75%, up 200 basis points from the prior quarter. Operating expenses declined 11% year-over-year, and our adjusted EBITDA loss narrowed 86% to approximately $300,000.
These results reflect disciplined execution over the past year, better manufacturing and sourcing, tighter cost controls, a leaner organization, and improved working capital management. The significance extends beyond this quarter. Every dollar of operating cash we eliminate reduces our future financing needs and allows more of the value created by future growth to accrue to shareholders. Our strategy centers on four distinct drivers of value creation. The first is achieving sustainable operating cash flow breakeven, and we've now reached that initial milestone. The second is restoring sustainable profitable growth in our core CytoSorb business. The third is opening the U.S. market through DrugSorb-ATR, and the fourth is unlocking the strategic value of HemoDefend-BGA. Each offers a different opportunity to create value, so our future is not dependent on any single commercial, regulatory, or strategic outcome.
Now I will ask Pete to take you through the financial results, the drivers of our cash flow improvement, and then I'll return to discuss the other three opportunities.
Pete? Thank you, Phil. I'll focus my comments on the four drivers behind our breakeven: gross margin, operating expenses, operating income, and adjusted EBITDA.
First of all, third quarter revenue was $9.7 million, up 3% year-over-year and 1% sequentially, led by an 18% increase in distributor and strategic partner sales. Gross margin. The most significant improvement in our P&L this quarter was gross margin. Product gross margin was 75%, up approximately 2 points from 73% in the second quarter and 5 points from 70% a year ago. It has improved every quarter this year from 69% in the first quarter. On revenue growth of about $243,000, gross profit rose about $662,000, or 10%, to $7.3 million, and cost of goods sold declined 15% to $2.4 million. These gains are structural. Over the past year, manufacturing and operations teams optimized our production process, improved sourcing of key materials, and drove efficiencies across production while aligning output with demand to keep inventory lean.
We believe these improvements are sustainable, and we are targeting product gross margins consistently in the mid-70% range. Operating expenses were $8.5 million, down 11%, or about $1 million from a year ago, and down 12%, or about $1.2 million from the second quarter. Excluding $250,000 of restructuring charges, they were down 13% year-over-year. SG&A fell 18% to 7.1, reflecting the full quarter benefit of actions we took over the past year, including the reduction of headcount by approximately 24%, restructuring of our commercial organization, and tightening cost controls across every function.
R&D was $1.1 million, up from $900,000 a year ago, reflecting lower grant income in the current year and regulatory work on DrugSorb-ATR, but down 21% from the second quarter. Operating loss and adjusted EBITDA. Higher gross profit and a lower cost base together drove significant improvement in operating performance. Operating loss improved 59%, or about $1.7 million to $1.2 million from $2.9 million a year ago, and improved about $1.5 million from $2.6 million in the second quarter. Adjusted EBITDA loss, which excludes the impact of non-cash foreign currency changes, non-cash stock compensation, and restructuring charges, improved 86% to approximately $284,000 from $2 million a year ago and $1.6 million in the second quarter, and has improved each quarter this year.
Adjusted EBITDA most closely tracks our underlying operating cash generation, and bringing it near break-even was fundamental to our ability to reach operating cash flow break-even this quarter. Net loss improved 42% to $1.8 million, or $0.58 per share, from $3.2 million, or $1.01 per share. Adjusted net loss, which excludes the same items, was $1.5 million, or $0.48 per share, versus $2.6 million, or $0.83 per share in the prior year. For the nine months ended September, revenue was $28.2 million, up 1%. Gross margin improved to 73% from 71%. Operating expenses fell 9% to $27.4 million, and adjusted EBITDA loss improved 45% to $4 million.
Operating loss improved 34%, or $3.5 million to $6.9 million, driven by $800,000 of higher gross profit and lower costs, including $1.1 million in selling, travel, and marketing, $1 million in compensation, $800,000 in financial, legal, and consulting, and $200,000 in R&D, all of which was partially offset by $600,000 of restructuring charges. Net loss was $11.4 million, or $3.62 per share, versus $2.7 million due to an $11 million swing in non-cash foreign currency, a $1.9 million loss this year against a $9.1 million gain last year. As Phil mentioned, we generated positive operating cash flow of approximately $43,000 in the third quarter, excluding $251,000 of restructuring payments, compared to a burn of $200,000 in the second quarter and $2.7 million a year ago.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
